Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Plasmacytoma

Monoclonal Gammopathy of Undetermined Significance

Smoldering Multiple Myeloma

Paraproteinemias

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

This is a non-interventional trial

Rafat Abonour, MD

This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research

The Indiana Myeloma Registry

Collection of Specimens and Clinical Data to Create A Bio-repository for the Multiple Myeloma Program: The Indiana Myeloma Registry

The primary objective of this study is to provide a mechanism to store comprehensive clinical, genomic, demographic, social, environmental and quality of life data from subjects with plasma cell dyscrasias

To collect data related to clonal evolution, tumor microenvironment, clinical outcomes, adverse events, environmental factors and quality of life that will provide the foundation to create hypotheses for future confirmatory studies.

Indiana University

Assistant Professor of Medicine

Nutritional and Metabolic Diseases

Symptoms and General Pathology

Amyloidosis

Immunoglobulin Light-chain Amyloidosis

Proteostasis Deficiencies

Metabolic Diseases

Hypergammaglobulinemia

AL Amyloidosis

Herbal and Botanical

All Drugs and Chemicals

Horse Chestnut

tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.

tissue banking

The Ohio State University Comprehensive Cancer Center

Don Benson

Don Benson, MD

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:

* Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live.
* Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups.
* Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.

The investigators propose to contact and interact with all patients with plasma cell dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical Center) for both surveillance and research purposes in order to develop interventions targeted to decrease their morbidity and mortality.

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis

Establish a database of myeloma patients diagnosed or living in the state of Ohio to track myeloma disease course, patient reported outcomes, morbidity, and patient survival.

Provide two-way communication with patients by providing information regarding multiple myeloma, local support groups, and standard of care procedures through active contact procedures

Offer patients, and occasionally spouses and family members, the opportunity to participate in tissue banking, observational, patient reported outcomes, and therapeutic clinical trials for their plasma cell dyscrasia.

Ohio State University Comprehensive Cancer Center

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Indiana Myeloma Registry	NCT03616483	Plasma Cell Dys...	This is a non-i...	18 Years -	Indiana University
The Indiana Myeloma Registry	NCT03616483	Plasma Cell Dys...	This is a non-i...	18 Years -	Indiana University
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource	NCT01408225	Plasma Cell Dys... Monoclonal Gamm... AL Amyloidosis Multiple Myelom...	tissue banking	18 Years -	Ohio State University Comprehensive Cancer Center

Spots Global Cancer Trial Database for plasma cell dyscrasias